Tower View Wealth Management LLC Has $1.62 Million Stock Holdings in United Therapeutics Corporation $UTHR

Tower View Wealth Management LLC increased its position in United Therapeutics Corporation (NASDAQ:UTHR) by 3,544.0% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,733 shares of the biotechnology company’s stock after buying an additional 2,658 shares during the quarter. Tower View Wealth Management LLC’s holdings in United Therapeutics were worth $1,621,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also added to or reduced their stakes in the company. Torren Management LLC acquired a new position in shares of United Therapeutics during the fourth quarter worth $26,000. Activest Wealth Management increased its stake in shares of United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 56 shares during the period. Entrust Financial LLC bought a new position in shares of United Therapeutics during the fourth quarter worth about $31,000. Wilmington Savings Fund Society FSB lifted its stake in shares of United Therapeutics by 125.6% in the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after acquiring an additional 49 shares during the period. Finally, Harbor Capital Advisors Inc. bought a new stake in United Therapeutics in the fourth quarter valued at approximately $48,000. Institutional investors own 94.08% of the company’s stock.

Analyst Ratings Changes

Several research analysts have issued reports on the stock. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. Oppenheimer increased their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Royal Bank Of Canada lowered their target price on shares of United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Morgan Stanley set a $516.00 target price on shares of United Therapeutics in a report on Thursday, May 7th. Finally, Cantor Fitzgerald upped their price target on shares of United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research report on Thursday, March 12th. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $619.42.

United Therapeutics Stock Down 1.2%

NASDAQ:UTHR opened at $543.39 on Friday. United Therapeutics Corporation has a twelve month low of $272.12 and a twelve month high of $609.35. The company has a fifty day moving average of $561.93 and a 200-day moving average of $525.46. The firm has a market capitalization of $23.07 billion, a P/E ratio of 20.06, a P/E/G ratio of 1.81 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). The company had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm’s revenue was down 1.6% compared to the same quarter last year. During the same period in the prior year, the company earned $6.63 earnings per share. On average, analysts anticipate that United Therapeutics Corporation will post 26.49 EPS for the current fiscal year.

Insider Activity

In other news, CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $558.40, for a total value of $5,584,000.00. Following the completion of the sale, the chief financial officer directly owned 18,876 shares in the company, valued at $10,540,358.40. This trade represents a 34.63% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 643,218 shares of company stock worth $363,705,304. 8.60% of the stock is owned by corporate insiders.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.